Pawel Petryszyn

List of Publications by Citations

Source: https://exaly.com/author-pdf/8328890/pawel-petryszyn-publications-by-citations.pdf

Version: 2024-04-09

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.



#	Paper	IF	Citations
7	Effectiveness of screening for atrial fibrillation and its determinants. A meta-analysis. <i>PLoS ONE</i> , 2019 , 14, e0213198	3.7	19
6	A panel of stomach-specific biomarkers (GastroPanel) for the diagnosis of atrophic gastritis: A prospective, multicenter study in a low gastric cancer incidence area. <i>Helicobacter</i> , 2020 , 25, e12727	4.9	12
5	The importance of the polymorphisms of the ABCB1 gene in disease susceptibility, behavior and response to treatment in inflammatory bowel disease: A literature review. <i>Advances in Clinical and Experimental Medicine</i> , 2018 , 27, 1459-1463	1.8	7
4	Faecal calprotectin as a diagnostic marker of inflammatory bowel disease in patients with gastrointestinal symptoms: meta-analysis. <i>European Journal of Gastroenterology and Hepatology</i> , 2019 , 31, 1306-1312	2.2	5
3	Is the use of esomeprazole in gastroesophageal reflux disease a cost-effective option in Poland?. <i>Journal of Comparative Effectiveness Research</i> , 2016 , 5, 169-78	2.1	2
2	Infliximab, adalimumab, golimumab, vedolizumab and tofacitinib in moderate to severe ulcerative colitis: comparative cost-effectiveness study in Poland. <i>Therapeutic Advances in Gastroenterology</i> , 2020 , 13, 1756284820941179	4.7	2
1	Aromatase Inhibitors and Risk of Metabolic and Cardiovascular Adverse Effects in Breast Cancer Patients Systematic Review and Meta-Analysis. <i>Journal of Clinical Medicine</i> , 2022 , 11, 3133	5.1	1